ERBB2 and neoplasm: Besides, anti-HER2 monoclonal antibodies could increase endocytosis of HER2 receptor, suppress angiogenesis [22, 23], and induce tumor cell lysis through antibody-dependent cell-mediated cytotoxicity (ADCC) [18] (Fig. 1).